2022-2030 Kidney Cancer Therapeutics & Diagnostics Market Research Report - Regional Analysis, Top Players, Growth, Shares, Revenue

Detailed TOC of 2022-2030 Kidney Cancer Therapeutics & Diagnostics Market Research Report - Regional Analysis, Top Players, Growth, Shares, Revenue

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rising Number of Kidney Cancer Cases
6.1.2 Increased R&D Expenditure of Pharmaceutical Companies
6.1.3 Increasing Incidences of Chronic Diseases and Aging Population
6.2 Market Restraints
6.2.1 High Cost Associated with Treatment
6.2.2 Low Success Rate in Clinical Trails for Cancer Drugs
6.2.3 Regulatory Issues
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Cancer Type
7.1.1 Renal Cell Carcinoma
7.1.2 Clear Cell Renal Cell Carcinoma
7.1.3 Papillary Renal Cell Carcinoma
7.1.4 Chromophobe Renal Cell Carcinoma
7.1.5 Others
7.2 By Therapy
7.2.1 Afinitor
7.2.2 Avastin
7.2.3 Inlyta
7.2.4 Nexavar
7.2.5 Proleukin
7.2.6 Votrient
7.2.7 Sutent
7.3 By Diagnostics
7.3.1 Biopsy
7.3.2 Intravenous pyelogram
7.3.3 CT Scan
7.3.4 Nephro-ureteroscopy
7.3.5 Ultrasound
7.3.6 Others
7.4 By End Users
7.4.1 Hospitals
7.4.2 Pharmaceutical Labs
7.4.3 Genomics Laboratories
7.4.4 Others
7.5 By Geography
7.5.1 North America
7.5.1.1 United States
7.5.1.2 Canada
7.5.1.3 Mexico
7.5.2 Europe
7.5.2.1 France
7.5.2.2 Germany
7.5.2.3 United Kingdom
7.5.2.4 Italy
7.5.2.5 Spain
7.5.2.6 Rest Of Europe
7.5.3 Asia-Pacific
7.5.3.1 China
7.5.3.2 Japan
7.5.3.3 India
7.5.3.4 Australia & New Zealand
7.5.3.5 South Korea
7.5.3.6 Rest of Asia-Pacific
7.5.4 Middle East & Africa
7.5.4.1 GCC
7.5.4.2 South Africa
7.5.4.3 Rest of the Middle East & Africa
7.5.5 South America
7.5.5.1 Brazil
7.5.5.2 Argentina
7.5.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Abbott Laboratories
9.2 Amgen
9.3 Bayer Healthcare
9.4 Cerulean Pharma
9.5 F. Hoffmann-La Roche
9.6 Genentech
9.7 GlaxoSmithKline
9.8 Novartis
9.9 Pfizer
9.10 Seattle Genetics
9.11 List Not Exhaustive
10. Future of the Market